Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma

다국어 초록 (Multilingual Abstract)

Background: The pathologic distinction between high-grade prostate adenocarcinoma (PAC) involving the urinary bladder and high-grade urothelial carcinoma (UC) infiltrating the prostate can be difficult. However, making this distinction is clinically important because of the different treatment modalities for these two entities. Methods: A total of 249 patient cases (PAC, 111 cases; UC, 138 cases) collected between June 1995 and July 2009 at Seoul St. Mary’s Hospital were studied. An immunohistochemical evaluation of prostatic markers (prostate-specific antigen [PSA], prostate-specific membrane antigen [PSMA], prostate acid phosphatase [PAP], P501s, NKX3.1, and α-methylacyl coenzyme A racemase [AMACR]) and urothelial markers (CK34βE12, p63, thrombomodulin, S100P, and GATA binding protein 3 [GATA3]) was performed using tissue microarrays from each tumor. Results: The sensitivities of prostatic markers in PAC were 100% for PSA, 83.8% for PSMA, 91.9% for PAP, 93.7% for P501s, 88.3% for NKX 3.1, and 66.7% for AMACR. However, the urothelial markers CK34βE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively. The sensitivities of urothelial markers in UC were 75.4% for CK34βE12, 73.9% for p63, 45.7% for thrombomodulin, 22.5% for S100P, and 84.8% for GATA3. Conversely, the prostatic markers PSA, PSMA, PAP, P501s, NKX3.1, and AMACR were also positive in 9.4%, 0.7%, 18.8%, 0.7%, 0%, and 8.7% of UCs, respectively. Conclusions: Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC. The optimal combination of prostatic and urothelial markers could improve the ability to differentiate PAC from UC pathologically.

참고문헌 (Reference)

1 Chang A, "Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung" 36 : 1472-1476, 2012

2 Jiang Z, "Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens" 123 : 231-236, 2005

3 Chibber PJ, "Transitional cell carcinoma involving the prostate" 53 : 605-609, 1981

4 Bates AW, "Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases" 36 : 32-40, 2000

5 Kalos M, "Prostein expression is highly restricted to normal and malignant prostate tissues" 60 : 246-256, 2004

6 Sweat SD, "Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases" 52 : 637-640, 1998

7 Silver DA, "Prostate-specific membrane antigen expression in normal and malignant human tissue" 3 : 81-85, 1997

8 Kunju LP, "Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma" 125 : 675-681, 2006

9 Bostwick DG, "Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases" 82 : 2256-2261, 1998

10 Parwani AV, "Prostate carcinoma with squamous differentiation: an analysis of 33 cases" 28 : 651-657, 2004

11 Parker DC, "Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas" 27 : 1-10, 2003

12 Higgins JP, "Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray" 31 : 673-680, 2007

13 Bowen C, "Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression" 60 : 6111-6115, 2000

14 Goldstein NS, "Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores" 117 : 471-477, 2002

15 Genega EM, "Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma" 13 : 1186-1191, 2000

16 Mhawech P, "Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma" 33 : 1136-1140, 2002

17 Lane Z, "Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder" 32 : 1322-1326, 2008

18 Comperat E, "Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma: a tissue microarray study of 158 cases" 448 : 319-324, 2006

19 Chuang AY, "Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma" 31 : 1246-1255, 2007

20 Xu J, "Identification and characterization of prostein, a novel prostate-specific protein" 61 : 1563-1568, 2001

21 Kamoshida S, "Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland" 21 : 1108-1111, 1990

22 Marchal C, "Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia" 19 : 715-718, 2004

23 Gelmann EP, "Expression of NKX3.1 in normal and malignant tissues" 55 : 111-117, 2003

24 Varma M, "Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature" 47 : 1-16, 2005

25 Dabbs DJ, "Diagnostic imunohistochemistry" Saunders-Elsevier 621-625, 2010

26 Bassily NH, "Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma" 113 : 383-388, 2000

27 Chang SS, "Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma" 57 : 1179-1183, 2001

28 Aslan G, "Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features" 202 : 93-98, 2006

29 He WW, "A novel human prostate-spe cific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer" 43 : 69-77, 1997